Lyell Immunopharma, Inc. (LYEL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US55083R2031
Lyell Immunopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 36,000.00 USD |
| Operating income | -269.40 m USD |
| EBIT | -274.45 m USD |
| Net income | -274.45 m USD |
| Diluted EPS – continuing operations | -16.06 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
More stocks
- 908 Devices Inc. (MASS)
- TSEC Corp (6443.TW)
- Advantage Solutions Inc. (ADV)
- Yulon Finance Corp. Pfd. (9941A.TW)
- Fullink Technology Co. LTD. (301067.SZ)
- Groupe Guillin SA (ALGIL.PA)
- Guangdong Lifestrong Pharmacy Co. Ltd. (301111.SZ)
- Trade-Van Information Services Co (6183.TW)
- Shanghai Jinfeng Wine Co Ltd (600616.SS)
- Nantex Industry Co Ltd (2108.TW)
- Xiamen Yanjan New Material Co Ltd (300658.SZ)
- Stenhus Fastigheter I Norden AB (SFAST.ST)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.